<DOC>
	<DOC>NCT01102231</DOC>
	<brief_summary>Radiochemotherapy is a standard for the treatment of unresectable stage III non-small cell lung cancer. The investigators goal is to study the efficacy and the toxicity for a promising association of new agents (cetuximab and pemetrexed) with concurrent radiotherapy.</brief_summary>
	<brief_title>Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>nonsquamous stage III nonsmall cell lung cancer measurable disease (RECIST 1.1) ECOG performance status 01 normal organ and marrow function prior chest radiation therapy history of any cancer other than NSCLC (except nonmelanoma skin cancer or carcinoma in situ of the cervix) within the last five years. Prior therapy with known specific inhibitors of the EGFR. history of severe allergic reaction to prior therapy with monoclonal antibodies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>